体外研究 (In Vitro) |
(5R)-5-Hydroxytriptolide (LLDT-8) (50-400 nM; 24 h) 可剂量依赖性地抑制 LPS (MS-X54539) 诱导的小鼠 BV-2 小胶质细胞 NO 生成。 (5R)-5-Hydroxytriptolide (50-150 nM; 6 h) 可呈剂量依赖性抑制小鼠 BV-2 小胶质细胞中 LPS 诱导的 iNOS、IL-1β 和 TNF-α mRNA 表达。 (5R)-5-Hydroxytriptolide (50-150 nM; 24 h) 可呈剂量依赖性抑制小鼠 BV-2 小胶质细胞中 LPS 诱导的 TNF-α 蛋白生成。 (5R)-5-Hydroxytriptolide (50-150 nM; 24 h) 可呈剂量依赖性抑制脂多糖 (LPS) 诱导的小鼠原代小胶质细胞中 NO 的生成,且不会降低细胞活力。 (5R)-5-Hydroxytriptolide (50-150 nM; 12-48 h) 在 150 nM 浓度下可于 48 h 时抑制小鼠 BV-2 小胶质细胞中 LPS 诱导的 iNOS 和 TLR4 蛋白表达,并在 24 h 时呈剂量依赖性抑制 LPS 诱导的 IκBα 磷酸化。 (5R)-5-Hydroxytriptolide (150 nM) 可部分抑制脂多糖 (LPS) 诱导的小鼠 BV-2 小胶质细胞中 NF-κB (p65) 的核转位。 (5R)-5-Hydroxytriptolide (40-400 nM; 24-72 h) 可在体外呈剂量依赖性地抑制亲本 A549 细胞和脑转移性 A549-BrM2 细胞的增殖。 (5R)-5-Hydroxytriptolide (40 nM; 7-14 days) 可降低亲本 A549 细胞和脑转移性 A549-BrM2 细胞的集落形成能力。 (5R)-5-Hydroxytriptolide (24 h) 可调控脑转移性 A549-BrM2 细胞的基因表达,抑制包括 DNA 复制和细胞周期在内的增殖相关通路,且能上调 Tp53,但不会显著诱导其负调控因子 Mdm2。 (5R)-5-Hydroxytriptolide (200-400 nM) 可剂量依赖性调控亲本 A549 细胞和脑转移性 A549-BrM2 细胞中的细胞周期调控蛋白 (Cyclin-B1、Cyclin-D1、p27),从而阻断细胞周期进程。 (5R)-5-Hydroxytriptolide (200-400 nM) 可选择性诱导脑转移性 A549-BrM2 细胞 (而非亲本 A549 细胞) 中 p53 蛋白积累,并调控两种细胞系中凋亡相关蛋白 (BAX、Bcl-2) 的表达以促进细胞凋亡。 (5R)-5-Hydroxytriptolide (200-400 nM; 24 h) 可在体外呈剂量依赖性诱导亲本 A549 细胞和脑转移性 A549-BrM2 细胞发生凋亡,且对 BrM2 细胞的作用更强。 (5R)-5-Hydroxytriptolide 可强效抑制多种体外免疫应答,包括丝裂原诱导的 T、B 细胞增殖、混合淋巴细胞反应以及炎症/Th1 型细胞因子的释放。 (5R)-5-Hydroxytriptolide (12.5-50 nM; 6 day) 可降低 RAW264.7 细胞中 RANKL/M-CSF 诱导的 TRAP 阳性破骨细胞样细胞的形成。 (5R)-5-Hydroxytriptolide (50 nM; 4 h pre-incubation) 可抑制 RAW264.7 细胞中 RANKL 诱导的 IκB 磷酸化,但不抑制 p38、JNK、ERK 或 Akt 的磷酸化。 (5R)-5-Hydroxytriptolide 可在体外抑制伴刀豆球蛋白 A 或 Sac 刺激的小鼠脾细胞中 IFN-γ 的产生。 (5R)-5-Hydroxytriptolide (48 h) 在小鼠脾淋巴细胞中表现出低细胞毒性,孵育 48 h 后的 CC50 为 256.6 nM。 (5R)-5-Hydroxytriptolide (48 h) 可抑制刀豆蛋白 A (ConA) 诱导的小鼠脾淋巴细胞增殖,孵育 48 h 后的 IC50 为 131.7 nM。 (5R)-5-Hydroxytriptolide (孵育 48 h) 可抑制 LPS 诱导的小鼠脾淋巴细胞增殖,孵育 48 h 后的 IC50 为 171.5 nM。 (5R)-5-Hydroxytriptolide (96 h) 可抑制小鼠脾淋巴细胞的混合淋巴细胞反应增殖,总孵育 96 h 后的 IC50 为 38.8 nM。 (5R)-5-Hydroxytriptolide (25-100 nM; 24 h) 可剂量依赖性地降低刀豆蛋白 A (ConA) 诱导的 BALB/c 小鼠脾淋巴细胞中 IL-2、IFN-γ、IL-4 和 IL-6 的产生,实验条件为在 25、50 和 100 nM 浓度下孵育 24 h。 (5R)-5-Hydroxytriptolide (25-100 nM; 24 h) 可剂量依赖性地降低 Sac 诱导的 BALB/c 小鼠脾淋巴细胞中 IFN-γ 和 TNF-α 的产生 (25、50 和 100 nM 浓度下孵育 24 h),但对 IL-12p40 或 IL-10 的产生无影响。
Real Time qPCR
| Cell Line: |
mouse BV-2 microglial cells |
| Concentration: |
50; 100; 150 nM |
| Incubation Time: |
6 h |
| Result: |
Dose-dependently inhibited LPS-induced mRNA expression of iNOS, IL-1β, and TNF-α. Significantly reduced expression at 50 nM. Caused a greater reduction at 100 nM. Caused the strongest reduction at 150 nM, with significant differences compared to LPS-only treatment at each concentration. |
ELISA Assay
| Cell Line: |
mouse BV-2 microglial cells |
| Concentration: |
50; 100; 150 nM |
| Incubation Time: |
24 h |
| Result: |
Dose-dependently reduced LPS-induced TNF-α protein production. Significantly inhibited TNF-α protein production at 150 nM. |
Western Blot Analysis
| Cell Line: |
mouse BV-2 microglial cells |
| Concentration: |
50; 100; 150 nM |
| Incubation Time: |
12 h, 24 h, 48 h |
| Result: |
Significantly reduced LPS-induced iNOS protein levels at 48 h at 150 nM. Reduced LPS-induced TLR4 protein levels at 48 h at 150 nM. Inhibited LPS-induced p-IκBα levels at 24 h in a dose-dependent manner, with significant inhibition observed at 150 nM. |
Western Blot Analysis
| Cell Line: |
Murine RAW264.7 cells |
| Concentration: |
50 nM |
| Incubation Time: |
4 h (pre-incubation); 0, 10, 30, 60 min (RANKL induction) |
| Result: |
Markedly inhibited the RANKL-induced increase in phosphorylated IκB (p-IκB) levels across all time points tested. Showed no significant effects on RANKL-induced phosphorylated p38, JNK, ERK, or Akt levels. |
ELISA Assay
| Cell Line: |
BALB/c splenic lymphocytes |
| Concentration: |
25; 50; 100 nM |
| Incubation Time: |
24 h |
| Result: |
Dose-dependently reduced ConA-induced production of IL-2, IFN-γ, IL-4, and IL-6. Dose-dependently reduced Sac-induced production of IFN-γ and TNF-α, but had no apparent effect on IL-12p40 or IL-10 production.
|
|
体内研究 (In Vivo) |
(5R)-5-Hydroxytriptolide (0.5-1 mg/kg;腹腔注射;再灌注后立即单次给药) 可显著小鼠降低脑梗死体积及促炎细胞因子的表达,对急性脑缺血/再灌注损伤具有保护作用。 (5R)-5-Hydroxytriptolide (1 mg/kg;腹腔注射;每两天一次;共 24 天) 对裸鼠非小细胞肺癌脑转移瘤生长具有抑制效果。 (5R)-5-Hydroxytriptolide (0.5-2 mg/kg;每日给药;持续 1 周) 可以剂量依赖方式减轻大鼠胶原诱导性关节炎。 (5R)-5-Hydroxytriptolide (1 mg/kg/天;口服;每日给药;持续至实验结束) 可在小鼠异基因骨髓移植模型中预防移植物抗宿主病,使大多数接受治疗的小鼠存活期延长至>60 天。 (5R)-5-Hydroxytriptolide (0.5-2 mg/kg;腹腔注射;每日;连续 7 或 14 天) 可呈剂量依赖性地保护小鼠免受博来霉素 (MS-I95244) 诱导的肺纤维化。 (5R)-5-hydroxytriptolide (0.4-1000 μg/kg;腹腔注射、口服;给药两次:攻击前 1 小时和攻击后 12 小时) 可剂量依赖性地抑制 DNFB 诱导的雌性 BALB/c 小鼠迟发型超敏反应,在 1000 μg/kg 口服剂量下可使耳肿胀程度最大降低 43.3%。 (5R)-5-hydroxytriptolide (40-1000 μg/kg;腹腔注射、口服;每日 1 次;连续 4 天) 可剂量依赖性地抑制 BALB/c 小鼠中 SRBC 诱导的体液免疫应答。
| Animal Model: |
ICR mice (male, 25-30 g, middle cerebral artery occlusion with monofilament technique, 1 h occlusion followed by reperfusion) |
| Dosage: |
0.5 mg/kg; 1 mg/kg |
| Administration: |
i.p.; single dose immediately post-reperfusion |
| Result: |
Significantly reduced infarct volumes in the cortex, striatum, and whole hemisphere (with edema correction) compared to vehicle. Remarkably attenuated cortical tissue mRNA expression of TNF-α, iNOS, and IL-1β in the ischemic penumbra 24 h after reperfusion. |
| Animal Model: |
nude mice (female, 5-6 weeks) |
| Dosage: |
1 mg/kg |
| Administration: |
i.p.; every other day; 24 days |
| Result: |
Showed a dramatic reduction in tumor radiance compared to vehicle controls by day 45. Significantly reduced the proportion of Ki67-positive tumor cells compared to vehicle controls. Significantly down-regulated Ki67 expression intensity compared to vehicle controls. Caused no obvious weight loss, abnormal behavior, organ weight alterations, or histopathological abnormalities in heart, liver, spleen, lung, or kidney. |
| Animal Model: |
Sprague-Dawley (male, weight 260 g) |
| Dosage: |
0.5 mg/kg; 1 mg/kg; 2 mg/kg |
| Administration: |
daily; 1 week |
| Result: |
Significantly reduced clinical arthritis scores in a dose-dependent manner at 1 mg/kg and 2 mg/kg doses. Significantly suppressed collagen-induced increases in IL-1β and IL-6 at 1 mg/kg and 2 mg/kg doses. Reduced iNOS protein expression at 1 mg/kg and 2 mg/kg doses. Reduced MMP-13 protein expression at 1 mg/kg and 2 mg/kg doses. Increased OPG gene expression at 1 mg/kg and 2 mg/kg doses. Decreased RANKL gene expression at 1 mg/kg and 2 mg/kg doses. Increased the OPG/RANKL ratio at 1 mg/kg and 2 mg/kg doses. Inhibited RANKL-induced NF-κB expression at 1 mg/kg and 2 mg/kg doses. |
| Animal Model: |
C57BL/6 (H-2b) (male, 8 to 10 weeks of age, allo-BMT model with 8.5 Gy total body irradiation prior to intravenous injection of BALB/c bone marrow and splenocytes) |
| Dosage: |
1 mg/kg/day |
| Administration: |
p.o.; daily; until end of experiment |
| Result: |
Extended survival of majority of treated mice to >60 days, whereas vehicle-treated mice died within 40 days. Showed inconspicuous weight loss compared to vehicle-treated mice. Maintained complete/near-complete donor chimerism in splenocytes. Induced T cell unresponsiveness to donor (H-2d) and host (H-2b) antigens while preserving responsiveness to ConA. Reduced spontaneous, ConA-stimulated, and host antigen-stimulated IFN-γ levels on day 7 post-transplantation. Normalized CD4+/CD8+ T cell ratio to 1.16, 1.18, 0.74, and 1.08 on days 7, 14, 21, and 28 post-transplantation, respectively. Increased Foxp3 mRNA expression in splenocytes on day 14 post-transplantation. |
| Animal Model: |
C57BL/6 (female, 6-8 weeks old, 20-22 g, bleomycin-induced lung fibrosis) |
| Dosage: |
0.5 mg/kg; 1 mg/kg; 2 mg/kg |
| Administration: |
i.p.; daily; 7 or 14 consecutive days |
| Result: |
Dose-dependently attenuated bleomycin-induced body weight loss and inhibited increases in lung index on days 7 and 14. Markedly reduced lung inflammation and fibrosis on day 14, with no obvious fibrotic foci in the 2 mg/kg group. Dose-dependently reduced total cells, neutrophils, and lymphocytes in bronchoalveolar lavage fluid. Reduced lung hydroxyproline levels. Enhanced lung superoxide dismutase (SOD) activity. Inhibited lung malondialdehyde production. Suppressed pro-inflammatory and pro-fibrotic cytokine production. Dose-dependently reduced transforming growth factor-β (TGF-β) levels, with 2 mg/kg returning TGF-β to near normal control levels on both days 7 and 14. |
| Animal Model: |
BALB/c (female, 6 to 8 weeks old, DNFB-sensitized delayed-type hypersensitivity model) |
| Dosage: |
0.4 μg/kg (i.p.); 4 μg/kg (i.p.); 40 μg/kg (i.p., p.o.); 200 μg/kg (p.o.); 1000 μg/kg (p.o.) |
| Administration: |
i.p.; two doses (1 h pre-challenge and 12 h post-challenge); p.o.; two doses (1 h pre-challenge and 12 h post-challenge) |
| Result: |
Reduced ear swelling to 17.7 mg, 15.3 mg, and 17.1 mg at i.p. doses of 0.4 μg/kg, 4 μg/kg, and 40 μg/kg, respectively. Reduced ear swelling to 33.8 mg, 30.0 mg, and 24.1 mg at p.o. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively. Achieved dose-dependent suppression of 20.5%, 29.5%, and 43.3% at p.o. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively. |
| Animal Model: |
BALB/c (6 to 8 weeks old, 8 mice per group, SRBC-immunized humoral immune response model) |
| Dosage: |
40 μg/kg (i.p., p.o.); 200 μg/kg (i.p., p.o.); 1000 μg/kg (i.p., p.o.) |
| Administration: |
i.p.; daily; 4 days; p.o.; daily; 4 days |
| Result: |
Reduced SRBC hemolysis to 0.175 OD, 0.162 OD, and 0.158 OD at i.p. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively. Suppressed hemolysis by 24.0% at 1000 μg/kg i.p. Reduced SRBC hemolysis to 0.236 OD, 0.342 OD, and 0.240 OD at p.o. doses of 40 μg/kg, 200 μg/kg, and 1000 μg/kg, respectively. Suppressed hemolysis by 36.3% at 1000 μg/kg p.o. |
|